A niche-monopoly refractive lens franchise resets after a China inventory shock and failed Alcon deal—now positioned for a shareholder-led, margin-and-growth recovery if China normalizes.
Overview
STAAR Surgical is the leading global pure-play in phakic intraocular lenses, with nearly all revenue derived from the EVO Implantable Collamer Lens platform used to correct myopia, hyperopia, and astigmatism without removing the natural lens. The procedure’s “implantable contact lens” proposition—reversible, cornea-sparing, and clinically attractive for high myopes—has supported long-term adoption, highlighted by surpassing 4 million ICLs sold globally in 2025. FY2025 results were highly volatile: net sales fell 23.7% to $239.4M, primarily due to a deliberate China distributor/channel inventory rebalance after weaker demand; importantly, ex-China sales still grew 6.6% to $161.7M. Profitability was depressed by one-time items, including ~$17.1M in merger-related costs tied to the terminated Alcon deal and ~$28.6M in restructuring, contributing to a net loss of ~$80.4M. Despite the downturn, gross margin stayed robust at ~76%, and the company ended with ~$187.5M cash and no debt, enabling self-funded recovery. Governance changed materially after the shareholder revolt that ended the Alcon transaction: Broadwood Partners (largest shareholder) gained significant influence, the board was reshaped, and interim co-CEOs were appointed in early 2026. Management is now pursuing a three-pronged plan to restore growth, expand margins, and restart innovation after merger disruption, with a key near-term question being the pace of China normalization.